Vancouver, BC, January 8, 2021--InMed Pharmaceuticals Inc. (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), announced top-line results from its 755-102-HV Phase 1 clinical trial ("Study 102").

Vancouver, BC, June 25, 2020--InMed Pharmaceuticals Inc. (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol, introduced details of IntegraSynTM, the Company's new approach to producing pharmaceutical-grade cannabinoids.

Vancouver, BC, May 26, 2020--InMed Pharmaceuticals Inc. (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol, reported financial results for the third quarter of fiscal year 2020 ("3Q20") which ended March 31, 2020.

Vancouver, BC, May 12, 2020--InMed Pharmaceuticals Inc. (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol, announced it has received regulatory and ethics board approval of its Clinical Trial Application to conduct its second Phase 1 trial with INM-755.

Vancouver, BC, January 8, 2020--InMed Pharmaceuticals Inc. (TSX: IN), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, announced it has received regulatory and ethics board approval of its Clinical Trial Application ("CTA") to conduct a Phase 1 trial in the Netherlands for INM-755, a cannabinoid-based topical cream.

Vancouver, BC, December 19, 2019--InMed Pharmaceuticals Inc. (TSX: IN), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, reported financial results for the three months ended September 30, 2019.